OtherBASIC SCIENCE INVESTIGATIONS
18F-Labeled BBN-RGD Heterodimer for Prostate Cancer Imaging
Zi-Bo Li, Zhanhong Wu, Kai Chen, Eun Kyoung Ryu and Xiaoyuan Chen
Journal of Nuclear Medicine March 2008, 49 (3) 453-461; DOI: https://doi.org/10.2967/jnumed.107.048009
Zi-Bo Li
Zhanhong Wu
Kai Chen
Eun Kyoung Ryu
Data supplements
Supplemental Data
Files in this Data Supplement:
In this issue
Journal of Nuclear Medicine
Vol. 49, Issue 3
March 2008
18F-Labeled BBN-RGD Heterodimer for Prostate Cancer Imaging
Zi-Bo Li, Zhanhong Wu, Kai Chen, Eun Kyoung Ryu, Xiaoyuan Chen
Journal of Nuclear Medicine Mar 2008, 49 (3) 453-461; DOI: 10.2967/jnumed.107.048009
Jump to section
Related Articles
Cited By...
- Dual-Targeted Molecular Imaging of Cancer
- Reply: Dual-Integrin {alpha}v{beta}3- and Gastrin-Releasing Peptide Receptor-Targeting PET Radiotracer (68Ga-BBN-RGD)
- Approaches to Multireceptor Targeting: Hybrid Radioligands, Radioligand Cocktails, and Sequential Radioligand Applications
- Clinical Translation of a Dual Integrin {alpha}v{beta}3- and Gastrin-Releasing Peptide Receptor-Targeting PET Radiotracer, 68Ga-BBN-RGD
- Bombesin-Targeted PET of Prostate Cancer
- In Vivo Cancer Dual-Targeting and Dual-Modality Imaging with Functionalized Quantum Dots
- Dosimetry and First Clinical Evaluation of the New 18F-Radiolabeled Bombesin Analogue BAY 864367 in Patients with Prostate Cancer
- 18F-Labeled Bombesin Analog for Specific and Effective Targeting of Prostate Tumors Expressing Gastrin-Releasing Peptide Receptors
- Small-Animal PET of Tumors with 64Cu-Labeled RGD-Bombesin Heterodimer
- Integrins in prostate cancer progression